KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $7.3 billion.

  • Regeneron Pharmaceuticals' Total Non-Current Liabilities rose 656.39% to $7.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.3 billion, marking a year-over-year increase of 656.39%. This contributed to the annual value of $7.3 billion for FY2025, which is 656.39% up from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Total Non-Current Liabilities is $7.3 billion, which was up 656.39% from $7.3 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $7.3 billion during Q3 2025, with a 5-year trough of $5.2 billion in Q1 2021.
  • In the last 5 years, Regeneron Pharmaceuticals' Total Non-Current Liabilities had a median value of $6.1 billion in 2021 and averaged $6.2 billion.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first skyrocketed by 5815.02% in 2021, then tumbled by 192.14% in 2022.
  • Regeneron Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $6.0 billion in 2021, then decreased by 1.22% to $5.9 billion in 2022, then grew by 5.76% to $6.3 billion in 2023, then rose by 9.3% to $6.8 billion in 2024, then rose by 6.56% to $7.3 billion in 2025.
  • Its last three reported values are $7.3 billion in Q4 2025, $7.3 billion for Q3 2025, and $6.6 billion during Q2 2025.